Related references
Note: Only part of the references are listed.Computer-aided Drug Design of Novel PLA2Inhibitor Candidates for Treatment of Snakebite
Lorane Izabel da S. Hage-Melim et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2012)
Structure-Based and Ligand-Based Drug Design for HER 2 Receptor
Hung-Jin Huang et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2010)
VPAC1 receptor binding site: Contribution of photoaffinity labeling approach
A. Couvineau et al.
NEUROPEPTIDES (2010)
Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques
Ryan Brenke et al.
BIOINFORMATICS (2009)
Design, Synthesis, and Docking Studies of Peptidomimetics Based on HER2-Herceptin Binding Site with Potential Antiproliferative Activity Against Breast Cancer Cell lines
Seetharama Satyanarayanajois et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2009)
Molecular Dynamics Simulations to Gain Insights into the Stability and Morphologies off K3 Oligomers from β2-microglobulin
Po-Sheng Fang et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2009)
Conserved Water Mediated H-bonding Dynamics of Inhibitor, Cofactor, Asp 364 and Asn 303 in Human IMPDH II
Hridoy R. Bairagya et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2009)
Disruption Mechanism in the Helix of SPF Peptide by Interchanging E5 and K10 Residues: Inference from Molecular Dynamics Study
P. N. Sunilkumar et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2009)
Molecular Modeling Studies of the Interaction Between Plasmodium falciparum HslU and HslV Subunits
Sangeetha Subramaniam et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2009)
Immunophilins and HIV-1 V3 Loop For Structure-Based Anti-AIDS Drug Design
Alexander M. Andrianov
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2009)
Molecular Dynamics Simulations to Investigate the Structural Stability and Aggregation Behavior of the GGVVIA Oligomers Derived from Amyloid β Peptide
Liang-Kai Chang et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2009)
Sequence Analysis, Structure Prediction, and Functional Validation of phaC1/phaC2 Genes of Pseudomonas sp LDC-25 and Its Importance in Polyhydroxyalkanoate Accumulation
Kabilan Sujatha et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2009)
Weighted Equation and Rules - A Novel Concept for Evaluating Protein-Ligand Interaction
Calvin Yu-Chian Chen
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2009)
An Insight to the Dynamics of Conserved Water Molecular Triad in IMPDH II (Human): Recognition of Cofactor and Substrate to Catalytic Arg 322
Hridoy R. Bairagya et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2009)
Conformational Dynamics of Human AP Endonuclease in Base Excision and Nucleotide Incision Repair Pathways
N. A. Timofeyeva et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2009)
Ligand-Based Dual Target Drug Design for H1N1: Swine Flu- A Preliminary First Study
Chien-Yu Chen et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2009)
Molecular Dynamics Simulations to Investigate the Aggregation Behaviors of the Aβ(17-42) Oligomers
Jian-Hua Zhao et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2009)
ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor
Diego Alvarado et al.
NATURE (2009)
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Jose Baselga et al.
NATURE REVIEWS CANCER (2009)
Structure-based view of epidermal growth factor receptor regulation
Kathryn M. Ferguson
ANNUAL REVIEW OF BIOPHYSICS (2008)
Functional and structural stability of the epidermal growth factor receptor in detergent micelles and phospholipid nanodiscs
Li-Zhi Mi et al.
BIOCHEMISTRY (2008)
Binding Properties of the C-terminal Domain of VIAF
William H. Bisson et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2008)
Study of early events in the protein folding of villin headpiece using molecular dynamics simulation
Uddhavesh B. Sonavane et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2008)
Computational anti-AIDS drug design based on the analysis of the specific interactions between immunophilins and the HIV-1 gp120 V3 loop. Application to the FK506-binding protein
Alexander M. Andrianov
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2008)
Molecular Modeling and Characterization of the B. thuringiensis and B. thuringiensis LDC-9 Cytolytic Proteins
A. Mahalakshmi et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2008)
What is the effective component in suanzaoren decoction for curing insomnia? Discovery by virtual screening and molecular dynamic simulation
Calvin Yu-Chian Chen et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2008)
Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo
Stephanie D. Allen et al.
JOURNAL OF IMMUNOLOGY (2007)
MolProbity: all-atom contacts and structure validation for proteins and nucleic acids
Ian W. Davis et al.
NUCLEIC ACIDS RESEARCH (2007)
ZRANK: Reranking protein docking predictions with an optimized energy function
Brian Pierce et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2007)
A semiempirical free energy force field with charge-based desolvation
Ruth Huey et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2007)
HER2 therapy - HER2 (ERBB2): functional diversity from structurally conserved building blocks
Ralf Landgraf
BREAST CANCER RESEARCH (2007)
New dual inhibitors of EGFR and HER2 protein tyrosine kinases
BE Fink et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities
NK Dakappagari et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
MC Franklin et al.
CANCER CELL (2004)
Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase
SS Hobbs et al.
ONCOGENE (2004)
Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase
SK Rabindran et al.
CANCER RESEARCH (2004)
Molecular approach to breast cancer treatment
Y Yarden et al.
SEMINARS IN ONCOLOGY (2004)
Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors
S Kamath et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Biologic and therapeutic role of HER2 in cancer
S Ménard et al.
ONCOGENE (2003)
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors
AW Burgess et al.
MOLECULAR CELL (2003)
Role of extracellular subdomains of p185c-neu and the epidermal growth factor receptor in ligand-independent association and transactivation
T Kumagai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
ZDOCK: An initial-stage protein-docking algorithm
R Chen et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2003)
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
HS Cho et al.
NATURE (2003)
EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization
KM Ferguson et al.
MOLECULAR CELL (2003)
Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)
A Wissner et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Molecular targets in breast cancer: current status and future directions
M Cristotanilli et al.
ENDOCRINE-RELATED CANCER (2002)
Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains
H Ogiso et al.
CELL (2002)
Disabling receptor ensembles with rationally designed interface peptidomimetics
A Berezov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
DB Agus et al.
CANCER CELL (2002)
Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer
DS Leonard et al.
BRITISH JOURNAL OF SURGERY (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
